Mochida Pharmaceutical Co (FRA:MFY) Moat Score: 0/10 (As of Jul. 09, 2026)


FRA:MFY Mochida Pharmaceutical Co Ltd FRA:MFY
68 GF Score
Price €16.80
GF Value €19.40
! 4 Warning Signs
View Full Analysis

What is Mochida Pharmaceutical Co Moat Score?

Mochida Pharmaceutical Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Mochida Pharmaceutical Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Mochida Pharmaceutical Co might have No Moat - No discernible moat.

Mochida Pharmaceutical Co  (FRA:MFY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Mochida Pharmaceutical Co Moat Score Related Terms

FRA:MFY
68GF Score
Mochida Pharmaceutical Co Ltd FRA:MFY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mochida Pharmaceutical Co (FRA:MFY) Overvalued in 2026?

Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued. The current stock price of €16.80 is trading 13.4% below its estimated GF Value™ of €19.40.

Key valuation signals for FRA:MFY:

  • Moat Score: 0
  • GF Value™: €19.40 vs. price of €16.80 (13.4% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the FRA:MFY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mochida Pharmaceutical Co Business Description

Other Exchanges 4534:Japan
Address 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
68GF Score

Get the complete analysis for FRA:MFY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.80
Price
€19.40
GF Value